The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04837859
Recruitment Status : Not yet recruiting
First Posted : April 8, 2021
Last Update Posted : September 14, 2023
Information provided by (Responsible Party):
Dr. Paul Broeckelmann, University of Cologne

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2027